$VTRS

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

Vaxcyte reported positive Phase III data for its pneumococcal vaccine. Caribou Biosciences halted its CAR-T program due to funding issues. Argenx discontinued Vyvgart for Sjögren's treatment. Viatris agreed to acquire Pacira Biosciences for $1.65 billion.

Caribou Biosciences (CRBU) is exploring strategic alternatives, including a potential sale, and will discontinue two CAR-T therapy programs. Viatris (VTRS) agreed to acquire Pacira BioSciences for $1.65B. Uber (UBER) will buy ezCater for $2.3B. Skydance (SKYD) completed its acquisition of Warner Bros. Discovery (WBD). True Food Kitchen filed for Chapter 11 bankruptcy.

HC Wainwright downgraded Pacira BioSciences to Neutral with a $36.50 price target, matching its recent share price. The downgrade follows Viatris' acquisition agreement at $36.50 per share, citing slower growth and competitive pressures.

Viatris acquires Pacira BioSciences for $1.65B in cash, adding Exparel and Zilretta. Ultragenyx sells a priority review voucher for $210M. M&A activity and financing conditions are shaping the pharma and biotech outlook.

Oppenheimer downgraded Pacira Biosciences from Outperform to Perform following its sale to Viatris. The stock has risen 44.4% in 5 days and 45.5% year-to-date.

Viatris (VTRS) and Opus Genetics (IRD) await FDA decision on MR-141, an eye drop for presbyopia, by October 17. Opus developed the drug and earns royalties, while Viatris holds global sales rights. Approval could boost Viatris' branded medicines portfolio and Opus' revenue, but market uptake is uncertain. Viatris has a $20B market cap and $14.7B debt, while Opus is a $340M gene-therapy company.

Viatris Inc. (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion, or $36.50 per share. Pacira's products, EXPAREL and ZILRETTA, generated $746 million in revenue and $177 million in adjusted EBITDA in the last 12 months. The deal is expected to close by the end of 2026 and be immediately accretive to Viatris' financial guidance. Viatris plans to leverage its global infrastructure to expand the reach of Pacira's products.

UBS maintained a 'Buy' rating for Viatris (VTRS) and raised its price target to $26.00 from $23.00. GuruFocus values VTRS at $11.44, indicating a 54.0% overvaluation at its current price of $17.61. The company has a GF Score™ of 61/100, reflecting moderate financial health. 11 gurus hold VTRS, with mixed activity in recent quarters.

UBS raised its price target on Viatris (NASDAQ:VTRS) to $26.00, citing growth drivers like cenerimod, China operations, and hormone therapy. VTRS shares are up 40% YTD. Q2 2026 earnings beat estimates, and guidance was raised. Oppenheimer initiated coverage with an outperform rating and $25.00 target. Piper Sandler raised its target to $13.00.